News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

How Much?! AbbVie (ABBV) Raises Niaspan Price Despite Study Failures


5/24/2013 7:49:00 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Over the past two years, two studies showed the Niaspan cholesterol drug did not benefit patients. Yet AbbVie has managed to maintain revenue generated by the pill using a simple business proposition – the drugmaker has consistently raised its price, Bloomberg News writes. And the tactic is drawing criticism at a time of rising health care costs and ongoing debate over prescription drug prices. The Abbott Laboratories now charges $4.78 per pill, up from $3.50 two years ago, a 37 percent increase. “I don’t know how you can justify it,” Robert Giugliano, a cardiologist at Brigham and Women’s Hospital in Boston and an associate professor of medicine at Harvard, tells the news service. “The balance of the data suggests that niacin has little if any role in” treating patients with cholesterol problems.

Help employers find you! Check out all the jobs and post your resume.

Read at PharmaLive


comments powered by Disqus
AbbVie
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES